Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to $2.9 million.

  • Fortress Biotech's Cash from Investing Activities changed N/A to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.9 million, marking a year-over-year decrease of 764444.44%. This contributed to the annual value of -$15.0 million for FY2024, which is 61326.68% down from last year.
  • As of Q3 2025, Fortress Biotech's Cash from Investing Activities stood at $2.9 million.
  • Fortress Biotech's Cash from Investing Activities' 5-year high stood at $53.4 million during Q4 2021, with a 5-year trough of -$21.3 million in Q1 2022.
  • Its 5-year average for Cash from Investing Activities is $662750.0, with a median of -$424500.0 in 2021.
  • Per our database at Business Quant, Fortress Biotech's Cash from Investing Activities soared by 350478.62% in 2021 and then tumbled by 2370952.38% in 2024.
  • Fortress Biotech's Cash from Investing Activities (Quarter) stood at $53.4 million in 2021, then crashed by 100.73% to -$391000.0 in 2022, then soared by 83.89% to -$63000.0 in 2023, then plummeted by 23709.52% to -$15.0 million in 2024, then soared by 119.13% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $6.1 million for Q2 2025, and $1.2 million during Q1 2025.